Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TAA013 vs lapatinib plus capecitabine in HER2-positive breast cancer
CTR20200806Phase 3Terminated
- Sponsor
- TOT BIOPHARM
- Start
- Jun 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TAA013 in breast cancer (2 arms), sponsored by TOT BIOPHARM. Primary endpoint: Progression-free survival (PFS) by IRC per RECIST v1.1. Started Jun 2020; status: terminated.
02
Drugs
TAA013
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20200806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200806.